Personalised melanoma vaccine cuts death or recurrence risk by 42%
A phase 3 trial of the personalised mRNA vaccine Intismeran plus Keytruda found a 42% lower risk of death or recurrence in 1,137 adults, with 82.2% of vaccine recipients cancer-free after two years.